Compound class:
Synthetic organic
Comment: CIAC001 is a cannabidiol (CBD) analogue [1]. Its molecular target is reported as pyruvate kinase M2 (PKM2). CIAC001 is hypothesised to stabilise PKM2 tetramers within the cytosol, which reduces monomer translocation to the nucleus and thus attenuates neuronal inflammation. This mechanism is proposed as a therapeutic strategy to treat opioid addiction, by targeting opioid-caused neuroinflammation.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
(1′R,2′R)-4-(1-(2H-1,2,3-Triazol-2-yl)ethyl)-5′-methyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2,6-diol |
Database Links | |
GtoPdb PubChem SID | 485206034 |
PubChem CID | 168510601 |
Search Google for chemical match using the InChIKey | AGJUGOFAIPQXTD-MWSTZMHHSA-N |
Search Google for chemicals with the same backbone | AGJUGOFAIPQXTD |
UniChem Compound Search for chemical match using the InChIKey | AGJUGOFAIPQXTD-MWSTZMHHSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | AGJUGOFAIPQXTD-MWSTZMHHSA-N |